Acoramidis Cuts Serious Heart Risks in ATTR-CM by 49% in Phase 3 Study
A recent phase 3 study showed that acoramidis (Attruby), an oral treatment for transthyretin amyloid cardiomyopathy (ATTR-...
Continue with Facebook
Sign up with your email
Become a member to get even more